N-acetylgalactosamine 4-sulfatase

DRUG4 trials

Sponsors

BioMarin Pharmaceutical

Conditions

Mucopolysaccharidosis VI

Phase 1

Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

CompletedNCT00048620

BioMarin PharmaceuticalMucopolysaccharidosis VI

Start: 2000-09-30End: 2005-11-30Updated: 2006-11-03

Phase 2

Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI

CompletedNCT00048711

BioMarin PharmaceuticalMucopolysaccharidosis VI

Start: 2002-03-31End: 2006-06-30Updated: 2009-08-25

Phase 3

Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

CompletedNCT00067470

BioMarin PharmaceuticalMucopolysaccharidosis VI

Start: 2003-09-30End: 2004-03-31Updated: 2009-12-24

Study of rhASB in Patients With Mucopolysaccharidosis VI

CompletedNCT00104234

BioMarin PharmaceuticalMucopolysaccharidosis VI

Start: 2004-02-29End: 2006-10-31Updated: 2010-02-02

Related Papers

The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases.

2021-04-1922 citations